NanoViricides Inc (NNVC)

05:52 AM

Volume Recap: Can NanoViricides Inc grow without external funding2026 Momentum Check & Consistent Return Strategy Ideas - baoquankhu1.vn

05:52 AM

Mar 12, 2026

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Beaver County Times

Mar 12, 2026

Mar 12, 2026

NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - The Asheville Citizen Times

Mar 12, 2026

Mar 11, 2026

NanoViricides Completes Manufacturing of NV-387 Oral Gummies, Prepares for Phase II Monkeypox Trial - citybuzz -

Mar 11, 2026

Mar 11, 2026

Aug Setups: Can NanoViricides Inc continue delivering strong returns2026 EndofMonth & Stepwise Trade Execution Plans - baoquankhu1.vn

Mar 11, 2026

Mar 11, 2026

Small cap wrap: NanoViricides, Millennial Potash, Gunnison Copper, Century Lithium… - Proactive financial news

Mar 11, 2026

Mar 11, 2026

NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial - Yahoo! Finance Canada

Mar 11, 2026

Mar 11, 2026

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete - Durham Herald Sun

Mar 11, 2026

Mar 11, 2026

Antiviral NV-387 heads to Phase II mpox trial with new gummy form - Stock Titan

Mar 11, 2026

Mar 10, 2026

Jobs Data: Can NanoViricides Inc continue delivering strong returnsMarket Volume Report & Community Verified Trade Signals - baoquankhu1.vn

Mar 10, 2026

Mar 06, 2026

Sell Signal: Is NanoViricides Inc subject to activist investor interest2025 Investor Takeaways & Low Risk Growth Stock Ideas - baoquankhu1.vn

Mar 06, 2026

Mar 04, 2026

NNVC Earnings History & Surprises | EPS & Revenue Results | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill

Mar 04, 2026

Mar 02, 2026

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - The Asheville Citizen Times

Mar 02, 2026

Mar 01, 2026

getLinesFromResByArray error: size == 0 What is NanoViricides Inc.’s TAM (Total Addressable Market)Portfolio Gains Report & Growth Focused Entry Reports - mfd.ru

Mar 01, 2026

Feb 23, 2026

US Stocks Recap: Is NanoViricides Inc forming a breakout patternJuly 2025 WrapUp & Community Trade Idea Sharing - baoquankhu1.vn

Feb 23, 2026

Feb 23, 2026

Aug Fed Impact: Can NanoViricides Inc continue delivering strong returnsQuarterly Earnings Report & Long-Term Safe Investment Plans - baoquankhu1.vn

Feb 23, 2026

Feb 21, 2026

NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387ICYMI - Proactive financial news

Feb 21, 2026

Feb 21, 2026

Growth Value: Will NanoViricides Inc benefit from rate cutsJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn

Feb 21, 2026

Feb 19, 2026

Small cap wrap: Aftermath Silver, M2i Global, NanoViricides, AtaiBeckley… - Proactive financial news

Feb 19, 2026

Feb 19, 2026

NanoViricides advances toward fully funded Phase II MPox trial in DRC - Proactive financial news

Feb 19, 2026

Feb 19, 2026

NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox study - Yahoo Finance

Feb 19, 2026

Feb 17, 2026

NanoViricides: Fiscal Q2 Earnings Snapshot - kare11.com

Feb 17, 2026

Feb 17, 2026

NanoViricides: Fiscal Second Quarter Earnings Overview - Bitget

Feb 17, 2026

Feb 15, 2026

Moving Averages: Is NanoViricides Inc exposed to political riskJuly 2025 Movers & Growth Focused Stock Reports - baoquankhu1.vn

Feb 15, 2026

Feb 13, 2026

Can NanoViricides Inc grow without external fundingJuly 2025 Review & Growth Focused Stock Reports - baoquankhu1.vn

Feb 13, 2026

Feb 12, 2026

Small cap wrap: BioVie, VivoPower, NanoViricides, Aftermath Silver... - Proactive financial news

Feb 12, 2026

Feb 12, 2026

NanoViricides seeks FDA orphan status for MPox drug - Yahoo Finance

Feb 12, 2026

Feb 12, 2026

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Bitget

Feb 12, 2026

Feb 12, 2026

New Mpox drug candidate NV-387 chases FDA orphan status - Stock Titan

Feb 12, 2026

Feb 12, 2026

NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX) - Barchart.com

Feb 12, 2026

Feb 10, 2026

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza WaveNV-387 is Effective Against H3N2 - Ventura County Star

Feb 10, 2026

Feb 10, 2026

Small cap wrap: Medicus Pharma, 1911 Gold, NanoViricides, Nextech3D.ai, NextSource Materials… - Proactive Investors

Feb 10, 2026

Feb 10, 2026

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - USA Today

Feb 10, 2026

Feb 10, 2026

NanoViricides seeks orphan drug status with US FDA for measles treatment - Yahoo Finance

Feb 10, 2026

Feb 10, 2026

Measles cases surge as NanoViricides seeks orphan status for NV-387 - Stock Titan

Feb 10, 2026

Feb 09, 2026

NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres - USA Today

Feb 09, 2026

Feb 07, 2026

Trading Recap: Is NanoViricides Inc part of any ETFJuly 2025 Drop Watch & Real-Time Buy Signal Alerts - baoquankhu1.vn

Feb 07, 2026

Feb 05, 2026

CEO Change: Is NanoViricides Inc undervalued by DCF analysisWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn

Feb 05, 2026

Feb 04, 2026

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Reno Gazette Journal

Feb 04, 2026

Feb 03, 2026

NanoViricides President Discusses Broad-Spectrum Antiviral Platform and Upcoming Phase II Trial for MPox Treatment - citybuzz -

Feb 03, 2026

Feb 02, 2026

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres - accessnewswire.com

Feb 02, 2026

Feb 02, 2026

Inside a single antiviral drug aimed at flu, COVID, RSV and Mpox - Stock Titan

Feb 02, 2026